Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank_resource:DB00872_DB04845_nanopub.RAmuzAwR4ZaHczG-ZXtuZHg-2S4GsOD1_9JkmuCANIaCo#assertion>. }
Showing items 1 to 6 of
6
with 100 items per page.
- drugbank_resource:DB00872_DB04845 type drugbank_vocabulary:Drug-Drug-Interaction assertion.
- drugbank_resource:DB00872_DB04845 label "DDI between Conivaptan and Ixabepilone - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone. The dose of ixabepilone must be reduced when used with strong inhibitors of CYP3A.1 In one published abstract, ixabepilone 20mg/m2 was the maximum tolerated dose in patients who were also receiving the CYP3A-inhibitor ketoconazole (400mg). [drugbank_resource:DB00872_DB04845]" assertion.
- drugbank_resource:DB00872_DB04845 identifier "drugbank_resource:DB00872_DB04845" assertion.
- drugbank_resource:DB00872_DB04845 title "DDI between Conivaptan and Ixabepilone - CYP3A4 Inhibitors (Strong) may increase the serum concentration of Ixabepilone. The dose of ixabepilone must be reduced when used with strong inhibitors of CYP3A.1 In one published abstract, ixabepilone 20mg/m2 was the maximum tolerated dose in patients who were also receiving the CYP3A-inhibitor ketoconazole (400mg)." assertion.
- drugbank:DB00872 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00872_DB04845 assertion.
- drugbank:DB04845 drugbank_vocabulary:ddi-interactor-in drugbank_resource:DB00872_DB04845 assertion.